“Is myeloablative dose intensity required in allogeneic HCT for lymphomas?”

Friday, April 14th, 2017

Walker Auditorium

12:30 p.m. – 1:30 p.m.

Lunch available on a first come, first served basis

Presented by:

Mohamed A. Kharfan-Dabaja, M.D., MBA, FACP

Professor of Oncologic Sciences and Senior Member

Department of Blood and Marrow Transplantation

Moffitt Cancer Center, Tampa

Learning Objectives:

Upon conclusion of this program, participants should be able to:

• Review published medical literature on role of reduced-intensity (RIC) and myeloablative (MAC) conditioning allogeneic HCT for lymphomas.
• Compare outcomes of RIC vs. MAC allogeneic HCT in lymphomas.
• Discuss alternative donor sources and strategies to reduce relapse after allogeneic HCT in lymphomas.

   

  “Speaker, Mohamed A. Kharfan-Dabaja, has no financial relationships to disclose or intentions to discuss off-label/ investigational use of a commercial product device.”

  Mayo Clinic College of Medicine and Science is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

            Mayo Clinic College of Medicine and Science designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

            Please direct all inquiries for non-physician CEU’s to Clinical Education at (3-0326).